Market Summary
USD19.38+0.27
Delayedas of 20 Sep 2023, 02:36 pm1.41%
PHR Stock Price
PHR RSI Chart
PHR Valuation
PHR Price/Sales (Trailing)
PHR Profitability
PHR Fundamentals
PHR Revenue
PHR Earnings
Price Action
52 Week Range
18.7740.00
(Low)(High)
Last 7 days
-10.2%
Last 30 days
-29.6%
Last 90 days
-37.6%
Trailing 12 Months
-30.3%
PHR Financial Health
PHR Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for PHR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-14 | VanDuyn Amy Beth | sold | -40,315 | 20.1579 | -2,000 | svp, human resources |
2023-09-14 | Hoffman Allison C | sold | -44,566 | 20.1656 | -2,210 | general counsel & secretary |
2023-09-14 | Davidoff Michael J. | sold | -59,537 | 20.1616 | -2,953 | svp, payer business |
2023-09-13 | Indig Chaim | sold | -133,323 | 20.3391 | -6,555 | chief executive officer |
2023-09-13 | VanDuyn Amy Beth | sold | -37,139 | 20.3391 | -1,826 | svp, human resources |
2023-09-13 | Gunzburg Janet | sold | -18,996 | 20.3388 | -934 | principal accounting officer |
2023-09-13 | Gandhi Balaji | sold | -80,481 | 20.3391 | -3,957 | chief financial officer |
2023-09-13 | Roberts Evan | sold | -79,464 | 20.3391 | -3,907 | chief operating officer |
2023-09-13 | Davidoff Michael J. | sold | -73,342 | 20.3391 | -3,606 | svp, payer business |
2023-09-13 | Linetsky David | sold | -2,420 | 20.341 | -119 | svp, life sciences |
Which funds bought or sold PHR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -31.58 | -11,146 | 21,361 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -1.16 | -102,284 | 1,910,060 | -% |
2023-08-18 | Legato Capital Management LLC | added | 39.37 | 222,401 | 879,599 | 0.12% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -58.28 | -12,029,400 | 8,040,580 | -% |
2023-08-15 | ZACKS INVESTMENT MANAGEMENT | added | 86.86 | 762,699 | 1,722,680 | 0.01% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -31.97 | -4,435,110 | 8,357,290 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | sold off | -100 | -248,893 | - | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 104 | 425,122 | 866,151 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -0.09 | -349,000 | 8,290,000 | 0.01% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -12,755 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Phreesia
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 5.1% | 2,676,879 | SC 13G | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 0.3% | 180,384 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | brown advisory inc | 5.8% | 3,068,782 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 7.34% | 3,872,425 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 8.7% | 4,564,585 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 15.2% | 7,797,879 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 11.7% | 6,010,340 | SC 13G/A | |
| May 10, 2021 | price t rowe associates inc /md/ | 10.7% | 5,402,206 | SC 13G/A |
Recent SEC filings of Phreesia
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 4 | Insider Trading |
Peers (Alternatives to Phreesia)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
UNH | 445.6B | 348.5B | -3.57% | -7.58% | 21.11 | 1.28 | 13.69% | 15.63% |
VEEV | 33.5B | 2.2B | 12.06% | 21.42% | 62 | 15 | 11.56% | 37.20% |
| MID-CAP | ||||||||
TDOC | 3.4B | 2.5B | -10.21% | -31.13% | -0.85 | 1.35 | 13.30% | 59.30% |
OMCL | 2.5B | 1.2B | -6.17% | -41.00% | -106.97 | 2.01 | -1.77% | -138.27% |
| SMALL-CAP | ||||||||
NXGN | 1.6B | 678.1M | 46.14% | 40.83% | 673.85 | 2.34 | 12.34% | 2970.73% |
MDRX | 1.4B | - | -1.07% | -22.58% | 22.47 | 1.63 | - | - |
PHR | 1.0B | 319.4M | -29.59% | -30.26% | -6.69 | 3.19 | 30.27% | 15.64% |
CCRN | 848.8M | 2.4B | -3.77% | -18.89% | 6.82 | 0.35 | -5.09% | -42.39% |
SLP | 815.2M | 55.7M | -11.62% | -23.93% | 78.48 | 14.64 | 7.05% | -12.17% |
HSTM | 654.2M | 274.0M | -1.02% | -2.78% | 50.83 | 2.39 | 5.60% | 81.56% |
HCAT | 582.9M | 284.6M | -13.51% | 0.59% | -3.96 | 2.05 | 7.33% | -1.68% |
TRHC | 279.0M | 338.1M | 0.49% | 104.56% | -2.92 | 0.83 | 22.28% | 17.91% |
OPRX | 141.3M | 61.6M | -11.20% | -48.63% | -9.85 | 2.3 | -4.03% | -105.54% |
Phreesia News
Returns for PHR
Cumulative Returns on PHR
-13.8%
3-Year Cumulative Returns
Risks for PHR
What is the probability of a big loss on PHR?
84.1%
Probability that Phreesia stock will be more than 20% underwater in next one year
75%
Probability that Phreesia stock will be more than 30% underwater in next one year.
69.5%
Probability that Phreesia stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does PHR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Phreesia was unfortunately bought at previous high price.
Drawdowns
Financials for Phreesia
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 6.0% | 319,364,000 | 301,401,000 | 280,910,000 | 262,344,000 | 245,156,000 | 228,296,000 | 213,233,000 | 197,021,000 | 179,570,000 | 163,572,000 | 148,677,000 | 139,684,000 | 134,063,000 | 129,871,000 | 124,785,000 | 118,453,000 | 110,366,000 | 104,328,000 | 99,889,000 | 97,874,667 | 97,300,000 |
| S&GA Expenses | -0.7% | 147,548,000 | 148,645,000 | 151,263,000 | 152,209,000 | 147,614,000 | 131,440,000 | 106,421,000 | 82,174,000 | 60,619,000 | 48,550,000 | 42,972,000 | 38,200,000 | 36,067,000 | 34,089,000 | 32,357,000 | 30,566,000 | 29,413,000 | 27,821,930 | 26,367,000 | 27,447,860 | 26,115,720 |
| R&D Expenses | 5.1% | 102,007,000 | 97,078,000 | 91,244,000 | 83,341,000 | 75,945,000 | 64,846,000 | 52,265,000 | 41,125,000 | 31,584,000 | 25,671,000 | 22,622,000 | 21,128,000 | 20,170,000 | 19,330,000 | 18,623,000 | 17,968,000 | 17,050,000 | 15,538,921 | 14,349,000 | 14,069,842 | 12,715,684 |
| EBITDA | 100.0% | - | -137,821,000 | -149,295,000 | -164,403,000 | -162,125,000 | -140,247,000 | -97,761,000 | -64,016,000 | -35,798,000 | -16,323,000 | -12,908,000 | -11,025,000 | -7,146,000 | -9,236,002 | -10,594,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.46 | -0.53 | -0.63 | -0.66 | -0.61 | -0.46 | -0.32 | -0.20 | -0.10 | -0.09 | -0.08 | -0.05 | -0.07 | -0.08 | - | - | - | - | - | - |
| Interest Expenses | -100.0% | - | 2,165,000 | 1,064,000 | -856,000 | -1,228,000 | -1,229,000 | -1,084,000 | -1,123,000 | -1,279,000 | -1,491,000 | -1,573,000 | -1,882,000 | -1,634,000 | -1,960,000 | -2,445,000 | -2,813,000 | -3,322,000 | -3,460,673 | -3,504,000 | -3,223,346 | -3,534,692 |
| Earnings Before Taxes | 6.4% | -151,497,000 | -161,881,000 | -175,663,000 | -184,355,000 | -180,559,000 | -158,161,000 | -117,979,000 | -79,513,000 | -49,867,000 | -32,067,000 | -27,243,000 | -24,456,000 | -20,310,000 | -21,447,000 | -22,073,000 | -21,521,000 | -23,320,000 | -18,464,950 | -15,062,000 | -13,517,900 | -10,347,800 |
| EBT Margin | 100.0% | - | -0.54 | -0.63 | -0.70 | -0.74 | -0.69 | -0.55 | -0.40 | -0.28 | -0.20 | -0.18 | -0.18 | -0.15 | -0.17 | -0.18 | - | - | - | - | - | - |
| Net Income | 6.1% | -152,486,000 | -162,435,000 | -176,146,000 | -184,576,000 | -180,752,000 | -158,429,000 | -118,161,000 | -79,806,000 | -50,176,000 | -32,154,000 | -27,292,000 | -22,864,000 | -18,588,000 | -19,710,000 | -20,293,000 | -21,705,000 | -23,440,000 | -18,534,000 | -15,063,000 | -13,310,666 | -11,622,000 |
| Net Income Margin | 100.0% | - | -0.54 | -0.63 | -0.70 | -0.74 | -0.69 | -0.55 | -0.41 | -0.28 | -0.20 | -0.18 | -0.16 | -0.14 | -0.15 | -0.16 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -74,443,000 | -94,855,000 | -118,055,000 | -132,008,000 | -119,092,000 | -93,130,000 | -54,051,000 | -20,404,000 | -17,793,000 | -8,351,000 | -8,542,000 | -11,198,237 | -6,922,000 | -6,189,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q1 | 2018Q1 |
| Assets | -3.8% | 340 | 354 | 370 | 397 | 426 | 459 | 494 | 529 | 551 | 561 | 327 | 338 | 160 | 161 | 159 | 156 | 163 | 59.00 | 57.00 |
| Current Assets | -8.7% | 219 | 240 | 262 | 287 | 316 | 349 | 386 | 464 | 494 | 507 | 272 | 303 | 128 | 130 | 132 | 129 | 136 | 33.00 | 36.00 |
| Cash Equivalents | -14.7% | 128 | 150 | 177 | 210 | 241 | 269 | 314 | 400 | 440 | 451 | 219 | 254 | 84.00 | 90.00 | 90.00 | 91.00 | 100 | 2.00 | 11.00 |
| Net PPE | - | - | - | - | - | - | - | - | - | - | - | 27.00 | 19.00 | 17.00 | 15.00 | 14.00 | 14.00 | 15.00 | 14.00 | 13.00 |
| Goodwill | 20.4% | 41.00 | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 | 8.00 | 8.00 | 8.00 | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Liabilities | 3.5% | 93.00 | 90.00 | 82.00 | 77.00 | 78.00 | 78.00 | 77.00 | 71.00 | 65.00 | 58.00 | 63.00 | 68.00 | 63.00 | 61.00 | 57.00 | 53.00 | 60.00 | 64.00 | 49.00 |
| Current Liabilities | 2.3% | 85.00 | 83.00 | 79.00 | 73.00 | 72.00 | 71.00 | 68.00 | 65.00 | 58.00 | 51.00 | 55.00 | 42.00 | 38.00 | 38.00 | 35.00 | 32.00 | 39.00 | 28.00 | 25.00 |
| Long Term Debt | 20.4% | 8.00 | 7.00 | 3.00 | 4.00 | 5.00 | 6.00 | 7.00 | 5.00 | 6.00 | 6.00 | 6.00 | 24.00 | 23.00 | - | 22.00 | - | - | - | - |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 1.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.00 | 19.00 | 19.00 | 19.00 | 28.00 | 19.00 |
| Shareholder's Equity | -6.3% | 247 | 264 | 288 | 320 | 348 | 381 | 417 | 458 | 487 | 503 | 263 | 270 | 98.00 | 100 | 102 | 102 | 103 | - | - |
| Retained Earnings | -5.7% | -680 | -643 | -606 | -568 | -527 | -481 | -429 | -383 | -347 | -322 | -311 | -303 | -296 | -290 | -284 | -280 | -278 | -210 | -167 |
| Additional Paid-In Capital | 2.5% | 971 | 947 | 927 | 912 | 896 | 881 | 861 | 849 | 840 | 832 | 580 | 574 | 395 | 391 | 386 | 383 | 381 | - | - |
| Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | 40.00 | 43.00 | 40.00 | 38.00 | 36.00 | 34.00 | 32.00 | 28.00 | 20.00 |
| Shares Outstanding | -100.0% | - | 53.00 | - | 53.00 | 52.00 | 52.00 | - | 51.00 | 51.00 | 45.00 | 45.00 | 39.00 | 38.00 | 37.00 | 37.00 | 36.00 | 7.00 | 2.00 | 2.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 15.0% | -59.64 | -70.15 | -90.12 | -112 | -115 | -102 | -74.71 | -32.65 | -8.79 | -4.49 | 3.00 | 0.00 | -2.28 | 1.00 | 1.00 | -4.25 | -0.49 | -1.39 | -2.13 | 3.00 | 2.00 |
| Share Based Compensation | 6.6% | 66.00 | 62.00 | 59.00 | 54.00 | 52.00 | 45.00 | 36.00 | 30.00 | 20.00 | 16.00 | 13.00 | 12.00 | 10.00 | 8.00 | 6.00 | 4.00 | 3.00 | 2.00 | 1.00 | 2.00 | 1.00 |
| Cashflow From Investing | -15.3% | -29.12 | -25.26 | -26.20 | -60.27 | -68.05 | -65.35 | -65.23 | -38.54 | -27.74 | -28.91 | -25.08 | -14.27 | -14.08 | -12.67 | -12.32 | -13.04 | -11.80 | -11.85 | -11.02 | -9.12 | -9.72 |
| Cashflow From Financing | -1.2% | -24.29 | -24.02 | -20.80 | -18.33 | -15.09 | -13.27 | 235 | 217 | 392 | 394 | 151 | 177 | 1.00 | 96.00 | 100 | 106 | 108 | 15.00 | 4.00 | -1.05 | -4.32 |
PHR Income Statement
2023-07-31Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jul. 31, 2023 | Jul. 31, 2022 | Jul. 31, 2023 | Jul. 31, 2022 | |
| Revenue: | ||||
| Total revenues | $ 85,830 | $ 67,867 | $ 169,675 | $ 131,221 |
| Expenses: | ||||
| Cost of revenue (excluding depreciation and amortization) | 14,449 | 14,873 | 29,356 | 29,259 |
| Payment processing expense | 15,852 | 12,554 | 31,942 | 24,712 |
| Sales and marketing | 37,244 | 38,341 | 74,657 | 78,372 |
| Research and development | 27,471 | 22,542 | 53,940 | 43,177 |
| General and administrative | 20,988 | 20,073 | 40,865 | 40,928 |
| Depreciation | 4,244 | 4,220 | 8,748 | 8,498 |
| Amortization | 2,537 | 1,599 | 5,023 | 3,203 |
| Total expenses | 122,785 | 114,202 | 244,531 | 228,149 |
| Operating loss | (36,955) | (46,335) | (74,856) | (96,928) |
| Other income, net | 50 | 38 | 8 | 7 |
| Interest income (expense), net | 786 | (206) | 1,504 | (589) |
| Total other income (expense), net | 836 | (168) | 1,512 | (582) |
| Loss before provision for income taxes | (36,119) | (46,503) | (73,344) | (97,510) |
| Provision for income taxes | (648) | (213) | (954) | (448) |
| Net loss | $ (36,767) | $ (46,716) | $ (74,298) | $ (97,958) |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.68) | $ (0.89) | $ (1.39) | $ (1.88) |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.68) | $ (0.89) | $ (1.39) | $ (1.88) |
| Weighted-average common shares outstanding, basic (in shares) | 53,794,060 | 52,325,209 | 53,574,584 | 52,135,250 |
| Weighted-average common shares outstanding, diluted (in shares) | 53,794,060 | 52,325,209 | 53,574,584 | 52,135,250 |
| Subscription and related services | ||||
| Revenue: | ||||
| Total revenues | $ 39,301 | $ 31,069 | $ 77,188 | $ 60,170 |
| Payment processing fees | ||||
| Revenue: | ||||
| Total revenues | 23,631 | 19,581 | 47,884 | 38,962 |
| Network solutions | ||||
| Revenue: | ||||
| Total revenues | $ 22,898 | $ 17,217 | $ 44,603 | $ 32,089 |
PHR Balance Sheet
2023-07-31Consolidated Balance Sheets - USD ($) $ in Thousands | Jul. 31, 2023 | Jan. 31, 2023 |
|---|---|---|
| Current: | ||
| Cash and cash equivalents | $ 127,677 | $ 176,683 |
| Settlement assets | 25,158 | 22,599 |
| Accounts receivable, net of allowance for doubtful accounts of $770 and $1,053 as of July 31, 2023 and January 31, 2023, respectively | 53,913 | 51,394 |
| Deferred contract acquisition costs | 820 | 1,056 |
| Prepaid expenses and other current assets | 11,662 | 10,709 |
| Total current assets | 219,230 | 262,441 |
| Property and equipment, net of accumulated depreciation and amortization of $68,044 and $59,847 as of July 31, 2023 and January 31, 2023, respectively | 22,816 | 21,670 |
| Capitalized internal-use software, net of accumulated amortization of $41,552 and $37,236 as of July 31, 2023 and January 31, 2023, respectively | 41,205 | 35,150 |
| Operating lease right-of-use assets | 227 | 569 |
| Deferred contract acquisition costs | 1,370 | 1,754 |
| Intangible assets, net of accumulated amortization of $3,256 and $2,549 as of July 31, 2023 and January 31, 2023, respectively | 12,994 | 11,401 |
| Deferred tax asset | 0 | 81 |
| Goodwill | 40,611 | 33,736 |
| Other assets | 1,989 | 3,255 |
| Total Assets | 340,442 | 370,057 |
| Current: | ||
| Settlement obligations | 25,158 | 22,599 |
| Current portion of finance lease liabilities and other debt | 7,112 | 5,172 |
| Current portion of operating lease liabilities | 416 | 934 |
| Accounts payable | 7,948 | 10,836 |
| Accrued expenses | 27,794 | 21,810 |
| Deferred revenue | 16,441 | 17,688 |
| Total current liabilities | 84,869 | 79,039 |
| Long-term finance lease liabilities and other debt | 8,055 | 2,725 |
| Operating lease liabilities, non-current | 216 | 349 |
| Long-term deferred revenue | 99 | 125 |
| Long-term deferred tax liabilities | 183 | 0 |
| Total Liabilities | 93,422 | 82,238 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.01 par value - 500,000,000 shares authorized as of both July 31, 2023 and January 31, 2023; 55,364,795 and 54,187,172 shares issued as of July 31, 2023 and January 31, 2023, respectively | 554 | 542 |
| Additional paid-in capital | 971,120 | 926,957 |
| Accumulated deficit | (680,382) | (606,084) |
| Treasury stock, at cost, 1,300,430 and 971,236 shares as of July 31, 2023 and January 31, 2023, respectively | (44,272) | (33,596) |
| Total Stockholders’ Equity | 247,020 | 287,819 |
| Total Liabilities and Stockholders’ Equity | $ 340,442 | $ 370,057 |
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.